Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
Aequus BioPharma Inc
Eton Pharmaceuticals Inc
LG Chem Ltd
Mallinckrodt Plc
Palatin Technologies Inc
Rhythm Pharmaceuticals Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
(liraglutide + setmelanotide hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-54640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LR-19021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9610 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Oct 20, 2020: City of Rockford $10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy
Sep 28, 2020: LG Chem’s obesity treatment wins ODD status in US
Jul 16, 2020: Rhythm Pharmaceuticals announces publication of results from phase 2 study of Setmelanotide in Bardet-Biedl Syndrome in diabetes, obesity and metabolism
Jul 06, 2020: MC4R agonist (LB54640) Poster Presentation at ADA 2020
Jul 01, 2020: Rhythm Pharmaceuticals announces submission of Marketing Authorization Application to the European Medicines Agency for setmelanotide in POMC and LEPR deficiency obesities
Jul 01, 2020: Rhythm Pharmaceuticals receives rare pediatric disease desigtion from U.S. Food and Drug Administration for setmelanotide for treatment of POMC and LEPR deficiency obesities
Jun 24, 2020: Positive results from Phase 2 study of once-weekly FluidCrystal formulation of setmelanotide in healthy volunteers with obesity
Jun 24, 2020: Rhythm Pharmaceuticals announces positive results from phase 2 study of once-weekly formulation of setmelanotide in healthy obese volunteers
Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
Jun 01, 2020: LG Chem Life Sciences Company receives FDA approval for IND application of LB54640 for the treatment of genetic disorders of obesity
May 13, 2020: Rhythm Pharmaceuticals announces FDA acceptance of new drug application for Setmelanotide for the treatment of POMC and LEPR deficiency obesities
Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
Mar 30, 2020: Rhythm Pharmaceuticals completes rolling submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR deficiency obesities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aequus BioPharma Inc, H2 2020
Pipeline by Eton Pharmaceuticals Inc, H2 2020
Pipeline by LG Chem Ltd, H2 2020
Pipeline by Mallinckrodt Plc, H2 2020
Pipeline by Palatin Technologies Inc, H2 2020
Pipeline by Rhythm Pharmaceuticals Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020